Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative medications function by mimicking the natural actions of GLP-1, a hormone produced by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these compounds enhance insulin production and reduce gl

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both glp-3 dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing differe